Preventing Cardiotoxicity in Breast Cancer Patients: PROACT
Research type
Research Study
Full title
Preventing cardiac damage in patients treated for breast cancer: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity (PROACT).
IRAS ID
213348
Contact name
David Austin
Contact email
Sponsor organisation
South Tees Hospitals NHS Foundation Trust
Eudract number
2017-001094-16
Duration of Study in the UK
2 years, 5 months, 31 days
Research summary
Breast cancer is the most common type of cancer amongst women worldwide, with over 50,000 new cases in the UK every year. Treatment often includes surgery, chemotherapy and radiotherapy and is highly effective.
However, the chemotherapy commonly given is a type called anthracyclines, which can cause damage to the heart cells. This may in turn lead to poorer heart function and heart failure.
In this study, we would like to understand if a commonly used heart drug called enalapril can stop patients who are receiving anthracycline-based chemotherapy for their breast cancer from getting heart damage.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
17/WM/0248
Date of REC Opinion
8 Aug 2017
REC opinion
Further Information Favourable Opinion